Atossa Therapeutics (ATOS) – Corporate News
-
Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Announce I-SPY 2 Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib
-
Atossa Therapeutics (ATOS) Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ATOS Stock Lookup